TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05038449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: Colchicine Tablets (Each tablet contains colchicine 0.5mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
Study: NCT06076187

Intervention type: OTHER
Intervention: Dual isotope method
Description: Dual isotope method

Intervention type: OTHER
Intervention: Dual isotope method
Description: Dual isotope method

Intervention type: OTHER
Intervention: Dual isotope method
Description: Dual isotope method
Study: NCT06121440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to audiobook
Description: Audiobook by children will be chosen by child psychologists. The books will be played to children via tablet computers. The researcher has a fairy tale therapy certificate. The audiobook listening will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. Audiobook will be listen to children only one day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playing musical-moving toy
Description: Musical-moving toy by children will be chosen by child psychologists. The toy will be played to children by the researcher. Playing musical-moving toy will start 5 minutes before the tracheostomy care process and will continue throughout the tracheostomy care process. The toy will be played to children only one day.
Study: NCT05413226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Celastrol
Description: Four increasing doses of Celastrol to each of five men.
Study: NCT05395156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Control group will receive TEAS on sham acupoint daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles Study group will receive TEAS on neurogenic acupoints daily from 3 days before menstruation to the 4th day of menstruation for 3 consequent menstrual cycles
Study: NCT06109350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting play exploration and early developmental intervention(SPEEDI)
Description: SPEEDI will be performed by the parents

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care will be performed by the parents
Study: NCT06180161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidomain intervention
Description: Integrating exercise cognitive training with nutrition, chronic disease management, oral health, fall prevention, traffic safety, psychosocial well-being, and sleep to enhance the effectiveness of improving cognitive function in the elderly community.
Study: NCT05828368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: Scaling and root planing is a deep cleaning below the gumline used to treat gum disease.~Gum disease is caused by a sticky film of bacteria called plaque. Plaque is always forming on your teeth, but if they aren't cleaned well, the bacteria in plaque can cause your gums to become inflamed.
Study: NCT06155474

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic galacto-oligosaccharide (GOS) Powder
Description: Prebiotic GOS Powder is a galacto-oligosaccharide ingredient low in mono-sugars. Scientific studies have shown positive effects of oligosaccharides, among which galacto-oligosaccharides, on growth of bifidobacterial, stool consistency bowel function and transit time, support of natural defenses and mineral absorption.~The product mainly consists of 97% dry matter with 69% prebiotic GOS, 23% lactose and 5% glucose and galactose as monosaccharides. These prebiotics have β-(4) glycosidic linkages and have been proven as safe product

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Starch Only
Description: The Starch Solution is a low-fat diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF + Starch
Description: ready-to-use therapeutic food and The Starch Solution is a low-fat diet.
Study: NCT05466292

Intervention type: OTHER
Intervention: Survey1
Description: Closed-ended survey on the level of knowledge, use, and dissemination of the CEC.

Intervention type: OTHER
Intervention: semi-structured interview_1
Description: the semi-structured interview concerns participants'motivations/expectations for implementing CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered

Intervention type: OTHER
Intervention: semi-structured interview_2
Description: semi-structured interview concerns participants motivations and expectations to be a member of the CEC, personal attitude towards the service, experience with CEC in terms of facilitators, problems, and critical evaluation on the service delivered.

Intervention type: OTHER
Intervention: semi-structured interview_3
Description: semi-structured interview concerns participants' experiences with the ethics consultation service provide by the Clinical Ethics Committee

Intervention type: OTHER
Intervention: survey_2
Description: survey of 20 multiple-choice questions and supplemented by free-text questions.
Study: NCT05598749

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arabic gum, sucrose and silicon dioxide mix

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum
Description: Propolis dry extract ESIT12 and carriers (arabic gum, sucrose and silicon dioxide mix)
Study: NCT04892199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide, 1.34 mg/mL
Description: Semaglutide 1.34 mg/ml, 1.5 ml pre-filled pen-injector is supplied in pens for injection containing 2.0 mg of the GLP-1RA semaglutide in 1.5 ml sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Direction for use will be given together with trial products.The possible doses of semaglutide are 0.25 mg, 0.50 mg and 1.0 mg. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide will remain on 0.5 mg once-weekly. The injection is administered subcutaneously once-weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide-placebo
Description: The semaglutide placebo pens contain XX-vehicle (no active drug) and are administered in the same way and volume as semaglutide. The semaglutide placebo is specially packed for this study and will be used in the study only. The initial weekly dose will be 0.25 mg for four weeks, then 0.5 mg for four weeks and then 1.0 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.0 mg semaglutide placebo will remain on 0.5 mg once-weekly. The injection is administered once-weekly. If the lowest tolerated dose is less than 0.5 mg of semaglutide placebo once-weekly, the patient will be excluded from the study.
Study: NCT02279615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: 50mg of mirabegron per day will be given.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin
Description: 0.4mg of flomax per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4mg of flomax per day.
Study: NCT06585085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In person PA sessions
Description: Group B women will have access to a weekly program of 3 face-to-face PA sessions. The face-to-face sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. They will also be offered at one or more times depending on the number of groups. Locations and times will be specified on the online booking software. Women can only register for 3 sessions per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive videoconference PA sessions
Description: Women in Group C will have access to a weekly program of 3 PA sessions via interactive videoconferencing. These sessions will have the same format as the face-to-face sessions with visualization of the APA professional, visualization of the participants (who can also choose to be masked). The PA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 3 sessions per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In person and by videoconference (mixed format) PA sessions.
Description: Women in Group D will have access to a weekly program of 3 mixed-format PA sessions, with 2 interactive distance learning sessions and 1 in-person session. The in-person sessions will be offered at one or more locations in the Clermont-Ferrand area, depending on the number of groups taking part. Locations and times will be specified on the online booking software. Women can only register for 1 face-to-face session per week. The other 2 sessions will be offered via interactive videoconferencing. These sessions will have the same format as the in-person sessions, with visualization of the APA professional, visualization of the participants. The APA professional will also see the participants, so he or she can correct positions and give individualized advice at any time. Schedules will be specified on the online booking software with the videoconference link. Women can only register for 2 videoconference's sessions per week.
Study: NCT05568797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Description: One dose of RSVPreF3 OA vaccine administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA vaccine
Description: One dose of RSVPreF3 OA vaccine administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLU vaccine
Description: One dose of FLU vaccine administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FLU vaccine
Description: One dose of FLU vaccine administered intramuscularly.
Study: NCT05603572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAT-101
Description: oral dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAT-101
Description: oral dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAT-201
Description: IT dosage form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAT-201
Description: IT dosage form
Study: NCT05456724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TO-O-1001
Description: TO-O-1001 ophthalmic solution in two concentration (0.05% and 0.1%) ocular administration only one drop in one eye

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is of same visual appearance and identical formulation as TO-O-1001, except the active component TO-168 ocular administration only one drop in one eye
Study: NCT06222177

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathophysiologic evaluation
Description: High-resolution manometry and pH study

Intervention type: DIAGNOSTIC_TEST
Intervention: Pathophysiologic evaluation
Description: High-resolution manometry and pH study
Study: NCT06639997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching doses of placebo as an IM injection or IV bolus
Study: NCT05708040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InPen Medtronic
Description: Patients with DM1 ≥ 18 years of age who initiate Inpen system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed 780G system
Description: Patients with DM1 ≥ 18 years of age who initiate Minimed 780G system.
Study: NCT06354049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki, originating in Japan, is a biofield therapy where a skilled practitioner places their hands on or above the body of the recipient or themselves to induce relaxation and promote healing.
Study: NCT06564311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obexelimab
Description: Obexelimab is a monoclonal antibody that simultaneously binds CD19 and FcyRIIb, resulting in down regulation of B cell activity
Study: NCT06399354

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acute intake of medium-chain fatty acids or long-chain fatty acids in patients
Description: The intake of an oil comprising of either medium -chain fatty acids or long-chail fatty acids

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute intake of medium-chain fatty acids or long-chain fatty acids in healthy individuals
Description: Acute intake of MCT and LCT in healthy individuals in a cross-over design
Study: NCT05279131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin ointment 1%
Description: Applied topically for 5 days over a field of approximately 100 cm\^2 on the face or balding scalp with AK.
Study: NCT04702451

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dispersion ablation + PVI
Description: Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VX1
Description: VX1-based dispersion mapping

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: Pulmonary vein antrum isolation
Study: NCT04847583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telacebec
Description: Telacebec 100 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Standard of care
Description: The Standard of Care treatment and administration thereof will be determined by the Investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-19 Standard of care
Description: The Standard of Care treatment and administration thereof will be determined by the Investigator
Study: NCT06564311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05406583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 0.5 mg/kg oral suspension
Description: DTG 0.5 mg/kg liquid suspension administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 0.5 mg/kg oral suspension
Description: DTG 0.5 mg/kg liquid suspension administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 5 mg Dispersible Tablets
Description: DTG 5 mg DT administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 5 mg Dispersible Tablets
Description: DTG 5 mg DT administered orally
Study: NCT05281757

Intervention type: DEVICE
Intervention: posterior stabilization for the cervical spine
Description: The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.
Study: NCT06099093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyl
Description: Fluorine-labeled small molecule, via intravenous infusion per protocol.
Study: NCT04974008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OST31-164
Description: Patients who will receive OST31-164 as a single agent every 3 weeks for 48 weeks with 4 doses constituting 1 treatment cycle (12 weeks per cycle). Each patient will receive treatment at a dose of 1x109 CFU until week 48 or until disease progression, unacceptable toxicity, or the patient meets any other treatment discontinuation criteria.
Study: NCT04179500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: pretomanid 200 mg (once daily) for 26 weeks (with meal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
Study: NCT04305028

Intervention type: DRUG
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 MG (Xarelto) twice daily, tablet

Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin 75-100 mg once daily, tablet

Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin 75-100 mg once daily, tablet
Study: NCT04179500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: moxifloxacin 400 mg (once daily) for 26 weeks (with meal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrazinamide
Description: pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)
Study: NCT05005936

Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: Undergo ABUS

Intervention type: PROCEDURE
Intervention: Ultrasonography
Description: Undergo WBUS
Study: NCT06258005

Intervention type: DIAGNOSTIC_TEST
Intervention: PocDoc
Description: PocDoc is a digital rapid 5-marker lipid test

Intervention type: DIAGNOSTIC_TEST
Intervention: PocDoc
Description: PocDoc is a digital rapid 5-marker lipid test

Intervention type: DIAGNOSTIC_TEST
Intervention: PocDoc
Description: PocDoc is a digital rapid 5-marker lipid test
Study: NCT04808843

Intervention type: DRUG
Intervention: Dienogest (BAY86-5258, Visanne)
Description: Following the physicians' decision.
Study: NCT03635827

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: NBTX-001 Xenon Inhaler
Description: The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
Study: NCT05947162

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: extinction training (nicotine cues)
Description: extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: extinction training (nicotine cues)
Description: extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: extinction training (nicotine cues)
Description: extinction training: were repeatedly presented with nicotine cue picture stimuli for extinction training, which lasted for 25 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: extinction training (neutral cues)
Description: extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: extinction training (neutral cues)
Description: extinction training: were repeatedly presented with neutral cue picture stimuli for extinction training, which lasted for 25 minutes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted smoking cessation
Description: Limiting cigarette intake within each day to a shorter interval, thus, no cigarette from 18:00 pm to 10:00 am.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time-restricted fasting
Description: Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted fasting
Description: Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 10:00 am.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Time-restricted fasting with food supplemnet
Description: Limiting food intake within each day to a shorter interval, thus, no food from 18:00 pm to 8:00 am, then supplied with breakfast.
Study: NCT04262193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: In each group, the participant will take 1 tablet (placebo or 20mg) 30 minutes before bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suvorexant Placebo
Description: Suvorexant Placebo